{{Expand Russian|topic=sci|Азоксимера бромид|date=July 2015}}
{{Infobox drug
| drug_name = 
| IUPAC_name = <nowiki>Poly[[1-(carboxymethyl)piperazin-1-ium-1,4-diyl bromide]ethylene- co-[(piperazin-1,4-diyl 1-oxide)ethylene]]</nowiki>
| image = Azoximer bromide.svg
| width = 250
| alt = 
| caption           =
<!-- Clinical data -->
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =
<!-- Pharmacokinetic data -->
| bioavailability = up to 89%
| protein_bound = 
| metabolism = 
| elimination_half-life = 25.4 hours (intravenous routes)
| excretion         =
<!-- Identifiers -->
| CAS_number = 892497-01-7
| ATCvet = 
| ATC_prefix = L
| ATC_suffix = 03AX
| PubChem = 
| DrugBank = 
| synonyms = Polyoxidonium, Synpol
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula = <nowiki>[[</nowiki>C<sub>8</sub>H<sub>15</sub>BrN<sub>2</sub>O<sub>2</sub>]<sub>x</sub>[C<sub>6</sub>H<sub>12</sub>N<sub>2</sub>O]<sub>y</sub>]<sub>n</sub>
| molecular_weight = 60000–100000 g/mol
}}

'''Azoximer bromide''' is a [[Macromolecule|macromolecular]] compound with high-molecular weight and high immunomodulating activity. It is used in Russia and CIS in treatment and prophylaxis of diseases connected with damage of immune system. It is a ''N''-oxidized polyethylene–piperazine derivative.

Azoximer bromide is registered in US Patent-5503830 from 1996,<ref>http://www.google.com/patents/about?id=s9cfAAAAEBAJ&dq=US+5503830</ref><ref>http://www.wikipatents.com/US-Patent-5503830/compounds-having-immunostimulating-activity-and-methods-of-use-thereof{{dead link|date=October 2016 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>http://www.freepatentsonline.com/EP0789586.html</ref> in the [[Russian Federation]] from 1996, under registration number 96/302/9, FS 42-3906-00.<ref>State Scientific Centre of Russian federation, Immunological Institute of Russian Federation Health Resort, CLINICAL ASPECTS OF USE OF IMMUNOMODULATOR POLYOXIDONIUM, Methodical handbook for doctors issued by State Scientific Centre of Russian Federation – Immunological Institute of Russian Federation Health Resort Moscow – 2003</ref>

'''Medical uses'''

In adults with secondary immunodeficient states as

- relapsing chronic bacterial infections

- relapsing chronic viral infections

- acute bacterial infections

- acute viral infections

- allergic diseases (pollinosis, bronchial asthma, atopic dermatitis)

- severe septic states

- postoperative complications - purulent infections

- when primary treatment develops cellular immunity decrease (cytostatic treatment, X-rays)

== References ==
{{reflist}}

[[Category:Copolymers]]
[[Category:Immunomodulating drugs]]
[[Category:Bromides]]


{{antineoplastic-drug-stub}}